Methods of weight loss in subjects with elevated HbA1c

Safety in the prior art was solved by using small-molecular uncoupling agents of 5-[(2,4-dinitrobenoxy)methyl]-1-methyl-2-nitro-1H-imidazole. and effectiveness issues, significantly reduce weight and liver fat, reduce HbA1c levels, and slow down the progress of non-alcoholic fatty liver disease.

CN118900692APending Publication Date: 2024-11-05RIVUS PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029098.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-04
Filing Date
2023-02-06
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In the prior art, methods for reducing weight and liver fat in subjects at HbA1c level have safety problems, such as 2,4-dinitrobenol (DNP) having high harmful effects and low therapeutic index, which cannot be safe and effective. Treat mitochondria-related disorders or conditions.

Method used

5-[(2,4-dinitrobenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is used as a new small molecule uncoupling agent to improve mitochondrial proton leakage Cell metabolism, reducing fat and sugar accumulation, is used to treat subjects with abnormal HbA1c levels and liver fat.

Benefits of technology

This method significantly reduces weight, reduces liver fat by more than 30%, reduces HbA1c level, slows down the progress of non-alcoholic fatty liver disease, and is safe and has no serious adverse events reported.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900692A_ABST
    Figure CN118900692A_ABST
Patent Text Reader

Abstract

The present disclosure provides a method of reducing body weight, body fat amount, liver fat in a subject having aberrant HbA1c levels, the method comprising administering to the subject a therapeutically effective amount of 5-[(2, 4-dinitrophenoxy) methyl]-1-methyl-2-nitro-1H-imidazole, or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This International PCT Application claims priority to and the benefit of U.S. Provisional Application No. 63 / 307,470, filed on February 7, 2022, and U.S. Provisional Application No. 63 / 382,426, filed on November 4, 2022, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0002] The present disclosure provides a method of reducing body weight, body fat mass, and liver fat in a subject with abnormal HbA1c levels, wherein the method comprises administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof. Background Art

[0003] Obesity is a well-known risk factor for the development of many common diseases such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). Obesity is best considered as any degree of excessive fat gain that poses a health risk. Glycosylated hemoglobin HbA1c is a biomarker that indicates a subject's blood sugar level and is used along with other markers to diagnose diabetes. Among the many factors that lead to elevated HbA1c are obesity and being overweight. Elevated HbA1c levels are associated with a higher risk of developing complications such as heart disease, liver disease, pancreatic disease, kidney disease, etc. Therefore, there is a great need for effective treatments for reducing the weight of subjects with elevated HbA1c.

[0004] Administration of chemical uncouplers of mitochondria as a method of reducing fat deposition has been a scientific goal for many years. Although there are several small molecules that uncouple mitochondrial oxidative phosphorylation, the most well-known is 2,4-dinitrophenol (DNP). Although DNP is known to uncouple with a robust effect, unfortunately, it is associated with an unacceptably high rate of significant adverse effects (J. Med. Toxicol. September 2011; 7 (3): 205-212). These adverse effects can include hyperthermia, tachycardia, sweating and tachypnea, ultimately leading to death. As a highly permeable small lipophilic acid, DNP is rapidly absorbed in the stomach. High concentrations are rapidly distributed and uncoupled immediately, generating high levels of heat in a short period of time. Therefore, DNP has a low therapeutic index and is extremely dangerous in the case of overdose. The Federal Food, Drug and Cosmetic Act of 1938 labeled DNP as "extremely dangerous and unsuitable for human use". Therefore, there is a need for uncouplers that can safely treat mitochondrial-related disorders or conditions.

[0005] 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is a novel small molecule uncoupler (Compound 1). It can function as a controlled metabolic accelerator (CMA). It is designed to effectively address the root cause of metabolic diseases, the accumulation of fat and sugar in the body. CMA works by improving cellular metabolism and increasing energy expenditure and calorie consumption, thereby reducing fat accumulation. Using a novel controlled and targeted approach, Compound 1 can increase mitochondrial proton leak, a continuous process that consumes energy in the body and accounts for 20%-40% of daily calories. Compound 1 utilizes the mitochondrial uncoupling mechanism to increase substrate utilization. Summary of the invention

[0006] In one aspect, the present disclosure provides a method for weight loss in a subject having abnormal HbA1c levels, wherein the method comprises administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0007] In certain embodiments, the abnormal HbA1c level is elevated HbA1c.

[0008] In another aspect, the present disclosure provides a method for reducing liver fat in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0009] In certain embodiments, the method results in a reduction in liver fat in the subject.

[0010] In certain embodiments, the methods are used to treat non-alcoholic fatty liver disease (NAFLD) in a subject with elevated liver fat.

[0011] In certain embodiments, the subject has a high body mass index (BMI).

[0012] In certain embodiments, the reduction in liver fat in the subject is at least 30% of the subject.

[0013] In certain embodiments, the reduction in liver fat in the subject with elevated HbAlc levels is at least 40%.

[0014] In certain embodiments, the method slows progression of nonalcoholic fatty liver disease.

[0015] In certain embodiments, the subject suffers from obesity, excess body fat, diabetes, high blood pressure / hypertension, dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.

[0016] In certain embodiments, the subject suffers from at least one symptom selected from decreased exercise tolerance, fatigue, tiredness, increased recovery time after exercise, and ankle swelling.

[0017] In certain embodiments, the subject has a disorder selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

[0018] In certain embodiments, the therapeutically effective amount of Compound 1 is from about 30 mg to about 1400 mg per day, from about 50 mg to about 100 mg per day, from about 150 mg to about 600 mg per day, or from 200 mg to 550 mg orally once daily.

[0019] In certain embodiments, the subject experiences weight loss following administration of Compound 1, wherein the weight loss is greater than 5%, 10%, 20%, or 30%.

[0020] In one embodiment, the subject experiences at least one of the following: i) weight loss of at least 5% or at least 30%; ii) blood pressure decreased by at least 5 mmHg; iii) HbA1c is reduced by at least 0.5% or at least 1.5%.

[0021] In another embodiment, the method slows the progression of obesity, hypertension, or diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 A 2-phase study design is shown.

[0023] Figure 2 Treatment effects of all doses are shown in the subject population with elevated HbA1c.

[0024] Figure 3 Weight loss in subjects with increased HbA1c is shown.

[0025] Figure 4 Shown are changes in body fat in a population of subjects with elevated HbA1c (mean ± SEM).

[0026] Figure 5Weight loss is shown for the overall population and the elevated HbA1c group.

[0027] Figure 6 Response rates of liver fat reduction from baseline to Day 61 (ie, > 30%) are shown.

[0028] Figure 7 The absolute and relative percent changes (%) in liver fat from baseline to Day 61 at 150 mg, 300 mg, and 450 mg of Compound 1 are shown.

[0029] Figure 8 The percent change (%) of liver stiffness parameters from baseline is shown.

[0030] Fig. 9 The reduction in glycated albumin in the total (FAS) population is shown (percent %). DETAILED DESCRIPTION definition

[0031] Although various embodiments and aspects of the present invention are shown and described herein, it is clear to those skilled in the art that such embodiments and aspects are provided only by way of example. Without departing from the present invention, those skilled in the art will appreciate that many variations, changes and replacements will be appreciated. It should be understood that various alternatives to the embodiments of the present invention described herein may be used to practice the present invention.

[0032] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents or portions of documents cited in this application (including but not limited to patents, patent applications, articles, books, manuals, and treatises) are expressly incorporated by reference in their entirety for any purpose.

[0033] 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is a new type of small molecule uncoupler. It has the following structure:

[0034] 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole can be prepared by the procedure described in WO 2018 / 129258.

[0035] In the present disclosure, Compound 1 and CM1 are interchangeable. They both refer to 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole.

[0036] As used herein, the term "a" or "an" means one or more.

[0037] The terms "comprise," "include," and "have" and their derivatives are used interchangeably herein as comprehensive, open-ended terms. For example, the use of "comprising," "including," or "having" means that whatever elements are comprised, have, or included are not the only elements encompassed by the subject of the clause containing the verb.

[0038] As used herein, the term "about" means a range of values ​​including a specified value that one of ordinary skill in the art would consider to be reasonably similar to the specified value. In some embodiments, the term "about" means within the standard deviation of measurements using generally acceptable measurements in the art. In some embodiments, "about" means a range extending to + / -10%, + / -5%, or + / -2% of a specified value. In some embodiments, "about" means a specified value.

[0039] As used herein, "treatment" or "treating" or "alleviation" or "improvement" or "reduction" are used interchangeably herein. These terms refer to methods for obtaining beneficial or desired results, including, but not limited to, therapeutic benefit. Therapeutic benefit means eradication or improvement of the underlying disorder being treated. In addition, therapeutic benefit is achieved by eradication or improvement of one or more physiological symptoms associated with the underlying disorder, such that improvement is observed in the subject, although the subject may still be suffering from the underlying disorder. Treatment includes causing a slowing of the development of clinical symptoms of the disease by administering a composition; suppressing the disease, that is, causing a reduction in clinical symptoms of the disease; inhibiting the disease, that is, preventing the development of clinical symptoms by administering a composition after the initial onset of symptoms; and / or alleviating the disease, that is, causing regression of clinical symptoms by administering a composition after the initial onset of clinical symptoms.

[0040] "Patient" or "subject" or "subject in need thereof" refers to a living organism suffering from or susceptible to a disease or condition that can be treated using the methods as provided herein. The term does not necessarily indicate that the subject has been diagnosed with a particular disease, but typically refers to an individual under medical supervision. Non-limiting examples include humans, other mammals.

[0041] As used herein, "administration" of a disclosed compound encompasses delivery of a compound as described herein, or a prodrug or other pharmaceutically acceptable derivative thereof, to a subject using any suitable formulation or route of administration (eg, as described herein).

[0042] "Pharmaceutically acceptable" refers to compounds, salts, compositions, dosage forms, and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.

[0043] As used herein, the language "pharmaceutically acceptable salts" refers to salts of the administered compound prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates, hydrates and clathrates thereof.

[0044] An "effective amount" is an amount sufficient to achieve the stated purpose (e.g., to achieve the target effect of its administration, to treat a disease, to reduce enzyme activity, to alleviate one or more symptoms of a disease or condition, to reduce viral replication in cells). An example of an "effective amount" is an amount sufficient to facilitate the treatment of a disease or alleviate one or more symptoms of a disease, which may also be referred to as a "therapeutically effective amount". "Relief" of one or more symptoms (and grammatical equivalents of this phrase) means reducing the severity or frequency of the one or more symptoms, or eliminating the one or more symptoms. Efficacy may also be expressed as a "fold" increase or decrease. For example, a therapeutically effective amount may have an effect of at least 1.2 times, 1.5 times, 2 times, 5 times, or more, compared to a control.

[0045] As used herein, the term "elevated body temperature" of a subject refers to an increase in body temperature associated with adverse effects (not limited to illness, physical discomfort or pain, coma, and death) for the subject. In a non-limiting embodiment, a significant increase in body temperature is an increase of about 0.5°C, about 1°C, about 1.5°C, about 2°C, about 2.5°C, about 3°C, about 3.5°C, about 4°C, about 4.5°C, about 5°C, about 5.5°C, about 6°C or more.

[0046] As used herein, "elevated liver fat" generally refers to when more than 8% of the liver weight is made up of fat. However, the AASLD defines elevated liver fat for NAFLD as 5%. Chalasani et al., Hepatology, 2018 67:328-357. Le et al. Diabetes, 2022;71(1 Suppl):119-OR. Others have suggested that any elevation in any level of liver fat is unhealthy. Minhdale et al. Diabetes 2022;71(1 Suppl):119-OR. Other researchers have suggested that the presence of any liver fat may be abnormal, [and that a liver fat content] cutoff of about 2% may be optimal for defining nonalcoholic fatty liver disease.

[0047] Treatment

[0048] In one aspect, provided herein is a method for weight loss in a subject having abnormal HbA1c levels, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0049] For people without diabetes, the normal range of hemoglobin HbA1c levels is between 4% and 5.6%. Hemoglobin HbA1c levels between 5.7% and 6.4% can be characterized as prediabetes and a higher risk of developing diabetes. Levels of 6.5% or higher are considered diabetes.

[0050] In certain embodiments, the abnormal HbA1c level is elevated HbA1c.

[0051] In another embodiment, the subject has an elevated HbA1c level greater than 5.7.

[0052] In certain embodiments, the subject suffers from obesity, excess body fat, diabetes, high blood pressure / hypertension, dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.

[0053] In certain embodiments, the subject suffers from obesity or excess body fat.

[0054] In certain embodiments, the subject has diabetes.

[0055] In certain embodiments, the diabetes is type 2 diabetes mellitus (T2DM).

[0056] In another embodiment, the subject suffers from a disorder selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

[0057] In certain embodiments, the subject suffers from at least one symptom selected from decreased exercise tolerance, fatigue, tiredness, increased recovery time after exercise, and ankle swelling.

[0058] In another aspect, provided herein is a method for reducing body fat mass in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0059] In another aspect, provided herein is a method for reducing liver fat in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0060] In certain embodiments, the subject in need thereof has elevated liver fat.

[0061] In certain embodiments, the above methods result in a reduction in liver fat in the subject.

[0063] In certain embodiments, the methods are used to treat non-alcoholic fatty liver disease (NAFLD) in a subject with elevated liver fat.

[0064] In certain embodiments, the subject has a high body mass index (BMI).

[0065] In certain embodiments, the reduction in liver fat in the subject is at least 30% of the subject.

[0066] In certain embodiments, the reduction in liver fat in the subject with elevated HbAlc levels is at least 40%.

[0067] In certain embodiments, the subject has a BMI greater than 28.0 kg / m 2 .

[0068] In certain embodiments, the subject has a BMI of 28.0-45.0 kg / m 2 between.

[0069] In certain embodiments, the weight loss is due to fat loss.

[0070] In certain embodiments, the weight loss is due to a decrease in liver fat.

[0071] In certain embodiments, the therapeutically effective amount is 150 mg and the reduction in liver fat in the subject is about 40%.

[0072] In certain embodiments, the therapeutically effective amount is 150 mg, and the reduction in liver fat in a subject with elevated HbA1c levels is about 43% of liver fat.

[0073] In certain embodiments, the therapeutically effective amount is 300 mg, and the reduction in liver fat in a subject with elevated HbA1c levels is about 70%.

[0074] In certain embodiments, the therapeutically effective amount is 300 mg, and the reduction in liver fat in a subject with elevated HbA1c levels is about 75%.

[0075] In certain embodiments, the therapeutically effective amount is 450 mg, and the reduction in liver fat in the subject is about 72%.

[0076] In certain embodiments, the therapeutically effective amount is 450 mg, and the reduction in liver fat in a subject with elevated HbA1c levels is about 86%.

[0077] In certain embodiments, the method slows progression of nonalcoholic fatty liver disease.

[0078] In certain embodiments, the present disclosure provides a method for reducing the risk of developing nonalcoholic steatohepatitis (NASH) in a subject with NAFLD, wherein the subject has elevated liver fat, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0079] On the other hand, patients with NAFLD have elevated adiposity or elevated HbA1c.

[0080] In certain embodiments, the subject suffers from obesity, excess body fat, diabetes, high blood pressure / hypertension, dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.

[0081] In certain embodiments, the methods slow the progression of obesity, hypertension, or diabetes.

[0082] In another aspect, disclosed herein is a method for treating fibrosis, progressive fibrosis, or progressive fibrosing liver disease (NASH) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

[0083] In certain embodiments, the therapeutically effective amount is from about 30 mg to about 1400 mg per day, from about 50 mg to about 100 mg per day, from about 150 mg to about 600 mg per day, or from 200 mg to 550 mg per day.

[0084] In certain embodiments, the therapeutically effective amount is about 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg or 600 mg per day.

[0085] In certain embodiments, the therapeutically effective amount is about 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg or 95 mg per day.

[0086] In certain embodiments, the therapeutically effective amount is about 150 mg, 300 mg, or 450 mg per day.

[0087] In certain embodiments, Compound 1 is administered orally once daily.

[0088] In certain embodiments, the subject experiences weight loss following administration of Compound 1, wherein the improvement comprises a weight loss of greater than 5%, 10%, >20%, or 30%.

[0089] In certain embodiments, the therapeutically effective amount of Compound 1 is about 150 mg and the body weight loss is greater than 10%.

[0090] In certain embodiments, the therapeutically effective amount of Compound 1 is about 300 mg and the body weight loss is greater than 20%.

[0091] In certain embodiments, the therapeutically effective amount of Compound 1 is about 450 mg and the body weight loss is greater than 30%.

[0092] In certain embodiments, the subject experiences at least one of the following: i) weight loss of at least 5% or at least 30%; ii) blood pressure decreased by at least 5 mmHg; iii) HbA1c reduction of at least 0.5%, iv) a reduction in lipids by at least 10%; and / or v) Liver fat reduction of at least 30%.

[0093] In certain embodiments, the subject experiences at least one of the following: i) weight loss of at least 5% or at least 30%; ii) blood pressure decreased by at least 5 mmHg; iii) HbA1c reduction of at least 0.5%, iv) a reduction in lipids by at least 10%; and / or v) Reduction of liver fat by at least 50%.

[0094] In certain embodiments, the subject experiences a reduction in HbAlc of at least 1.5%.

[0095] In certain embodiments, the methods slow the progression of obesity, hypertension, or diabetes.

[0096] Drug dosage form

[0097] The present disclosure includes novel pharmaceutical dosage forms of Compound 1 or a pharmaceutically acceptable salt thereof. The dosage forms described herein are suitable for oral administration to a subject. The dosage form may be in any form suitable for oral administration, including but not limited to capsules or tablets. In some embodiments, the present disclosure provides a single unit dose of capsules or tablets containing from about 30 mg to about 1400 mg, from about 100 mg to about 1000 mg, from about 150 mg to about 600 mg, or from 200 mg to 550 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, Compound 1 is administered in a hydroxypropyl methylcellulose capsule.

[0098] In some embodiments, the amount of Compound 1 in a unit dose is about 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 150 mg, 170 mg, 200 mg, 250 mg, 300 mg, 340 mg, 350 mg, 400 mg, 450 mg, 500 mg, 510 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, or 1400 mg. In some embodiments, the single unit dosage form is a capsule. In some embodiments, the single unit dosage form is a tablet.

[0099] In some embodiments, the amount of compound 1 in a unit dose is about 30 mg, 100 mg, 200 mg, 500 mg, 600 mg, 1050 mg, or 1400 mg. In some embodiments, the amount of compound 1 in a unit dose is about 200 mg, 400 mg, or 550 mg. In some embodiments, the amount of compound 1 in a unit dose is about 170 mg, 340 mg, 510 mg. In some embodiments, the amount of compound 1 in a unit dose is about 150 mg, 300 mg, 450 mg.

[0100] Route of administration

[0101] In therapeutic use for controlling or preventing weight gain in mammals, the compounds of the present disclosure or pharmaceutical compositions thereof may be administered orally or parenterally.

[0102] Example 1: Phase 2a Study of Compound 1 in Subjects with Elevated Liver Fat and High Body Mass Index (BMI)

[0103] This is a 61-day, randomized, double-blind, placebo-controlled trial evaluating the efficacy of tadalafil in patients with nonalcoholic fatty liver disease (NAFLD), elevated liver fat (>8%), and elevated body mass index (BMI) (28 to 45 kg / m 2 The safety and efficacy of 3 doses of orally administered Compound 1 were compared with placebo in subjects with ≥5 years of age. Subjects were stratified by glycated hemoglobin (HbA1c ≥ 5.7%). The primary endpoint was the relative change in liver fat content from baseline to day 61 as assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF); secondary endpoints included changes in safety, body composition, weight, glycemic control, and inflammatory markers.

[0104] Eighty subjects were enrolled (placebo n=20, compound 1 150mg n=20, 300mg n=21, 450mg n=19). At baseline, HbA1c was elevated in 40% of subjects. On day 61, the absolute and relative reductions in liver fat in compound 1-treated subjects and HbA1c subsets were highly significant (p<0.0001 relative to placebo). Responder analysis using 30% or greater liver fat reduction measured by MRI-PDFF showed that for compound 1 150mg, 300mg and 450mg doses, there were responses in 40%, 71% and 72%, respectively, and in the HbA1c subset, 43%, 75% and 86%, compared to 0-5% for placebo (p<0.05 for all comparisons). Compound 1 treatment was associated with significant reductions in total body fat, body weight, inflammatory markers and glycated albumin. Lean body mass was preserved. No serious adverse events occurred. Six subjects discontinued prematurely, 3 on Compound 1 (150 mg n=2, 300 n=1) and 3 on placebo. Diarrhea and flushing (most commonly mild) occurred in 35% and 25% of Compound 1 subjects, respectively.

[0105] Study Design

[0106] This is a Phase 2, single-center, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the safety and efficacy of Compound 1 in healthy subjects with high BMI and evidence of elevated liver fat. Subjects were screened over a 45-day period and eligible subjects were randomized to receive a once-daily oral dose of Compound 1 of 150 mg, 300 mg, or 450 mg or matching placebo under fasting conditions for 61 days. Randomization was stratified by glycated hemoglobin A1c (HbA1c), with normal baseline defined as HbA1c <5.7% and high baseline defined as HbA1c ≥5.7%. The final follow-up visit was performed within 10 to 14 days after the last dose. See Figure 1 .

[0107] Randomization will be blocked and stratified by HbA1c. Subjects will be stratified into two HbA1c strata: one subgroup of subjects with normal baseline HbA1c defined as HbA1c <5.7% and another subgroup of subjects with high baseline HbA1c defined as HbA1c between 5.7% and 9.0%, inclusive.

[0108] Target The primary efficacy and safety objectives of this study are to: effect: ■ To evaluate the reduction in liver fat content from baseline to Day 61 as assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in subjects with elevated BMI treated with Compound 1 compared to placebo. Security: ■ To evaluate the safety and tolerability of 61 days of repeated daily dosing of Compound 1 in overweight and obese subjects as defined by BMI. The secondary objectives of this study are to: ■ To assess the rate and amount of body weight loss following 61 days of Compound 1 treatment. ■ To evaluate the change from baseline in total body fat gain assessed by MRI following 61 days of Compound 1 treatment. ■ Characterize the pharmacokinetic (PK) profiles of Compound 1 and its metabolites DNP and M1 during 61 days of dosing in subjects with high BMI. ■ To evaluate and correlate changes from baseline in measures of liver composition and changes in liver fat content following dosing with Compound 1. ■Study the pharmacodynamic (PD) effects of compound 1 on metabolic and cardiovascular risk factors. ■Investigation of the PD effects of compound 1 on metabolomic, proteomic and lipidomic profiles. ■ Characterize the dose / exposure relationship of efficacy and PD effects of Compound 1, where data permit.

[0109] Inclusion Criteria To be eligible, subjects must meet all of the following inclusion criteria: 1. Adult male or female, aged 28 to 65 years (inclusive) at the time of informed consent, with a BMI of 28.0 and 45.0kg / m 2 Between (including the end values). a. Female subjects of childbearing potential must be non-lactating at the time of screening, confirmed not pregnant by a negative urine pregnancy test, and agree to continue to use an effective contraceptive method for at least 4 weeks prior to the first administration of study drug or a barrier method for 2 weeks until 30 days after the last dose of study drug. b. Female subjects of childbearing potential should not donate eggs during the study and for at least 30 days after the last dose of study drug. c. Female subjects without childbearing potential must be surgically infertile (e.g., hysterectomy, bilateral tubal ligation, oophorectomy) or postmenopausal (no menstruation for >1 year at screening and follicle stimulating hormone (FSH) >40U / L). d. Male subjects who have not undergone vasectomy and / or subjects who have undergone vasectomy but have not had 2 post-operative negative sperm tests must agree to use an acceptable method of contraception from the time of the first dose of study drug until 30 days after the last dose of study drug and not to donate sperm during the study and for at least 30 days after the last dose of study drug.

[0110] Exclusion criteria Subjects were excluded from the study if any of the following criteria were met: 1. Insulin-controlled diabetes mellitus. 2. Pregnant or breastfeeding or planning to become pregnant. 3. Intolerance to magnetic resonance imaging (MRI) or conditions that contraindicate MRI procedures, including but not limited to inability to fit into an MRI scanner or small surgical clamps / metal implants / shrapnel. Subjects must not suffer from claustrophobia, have a history of claustrophobia, or be intolerant of enclosed or small spaces. 4. Weight gain or loss >5% in the 3 months before the study, or weight gain or loss >10% in the 6 months before screening. 5. History of lap banding, intragastric balloon, duodenal-jejunal sleeve, or bariatric surgery within 5 years of screening, plan to undergo bariatric surgery before the end of study participation, or plan to lose weight through special diet, exercise program, or both during this study. 6. History of malignant hyperthermia. 7. History of chronic, severe, recurrent rash of unknown cause. 8. History of clinically significant cardiovascular disease or current clinically significant cardiovascular disease, including but not limited to transient ischemic attack, stroke, arrhythmia, syncope, unstable angina, myocardial infarction within 6 months prior to screening, congestive heart failure, or uncontrolled hypertension. (Uncontrolled hypertension is defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg based on the average of three resting measurements in the sitting position using an appropriately sized cuff). 9. Resting heart rate <45 or >110 bpm. 10. Based on screening ECG or based on medical history: a. Significant baseline prolongation of the QT / QTcF interval (e.g., repeated demonstration of a QTcF interval >450 ms (males) and >470 ms (females)). b. History of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome) or family history of unexplained sudden cardiac death. 11. Kidney disease, kidney transplantation, or estimated glomerular filtration rate (eGFR) < 50 mL / min / 1.73 m based on the CKD-EPI creatinine equation (NKF 2009; https: / / www.kidney.org / content / ckd-epi-creatinine-equation-2009) 2 . 12. Severe lung diseases requiring long-term daily medication, including chronic obstructive pulmonary disease (COPD), emphysema, pulmonary fibrosis, or asthma. 13. Untreated obesity hypopnea syndrome (OHS) or obstructive sleep apnea (OSA). 14. History of or active (acute or chronic) liver disease other than non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), such as but not limited to autoimmune liver disease, viral hepatitis, hereditary hemochromatosis, primary biliary cirrhosis, Wilson's disease, alpha-1-antitrypsin deficiency, alcoholic liver disease, acute fatty liver of pregnancy, or drug-induced (including acetaminophen) liver disease. 15. History of or treatment for clinically significant gastroparesis, inflammatory bowel disease, or any upper gastrointestinal surgery, except cholecystectomy or minor gastric surgery approved by the Medical Monitor. 16. History of cirrhosis and / or decompensated liver function (including ascites, hepatic encephalopathy or variceal bleeding). 17. History of acute pancreatitis or chronic pancreatitis of any cause within one year of screening. 18. Serum triglyceride concentration exceeds 500 mg / dL. 19.HbA1c>9.0%. 20. Family (maternal / father / sibling) and / or personal history of retinal detachment at any time in the past. 21. Any history or current diagnosis of glaucoma. 22. Evidence of the following screening ophthalmological examinations: a. Peripheral retinal pathology requiring treatment, retinal breaks, or retinal lesions requiring treatment. b. Diabetic retinopathy with macular exudates or macular edema as shown by optical coherence tomography (OCT) and examination. c. Any active macular disease that affects vision, including macular pucker (epiretinal membrane) and macular degeneration. d. Visually significant cataract determined by an ophthalmologist. e. Any previous intravitreal injection of anti-VEGF agents for macular degeneration. f. Previous history of vitrectomy. 23. History of malignancy within 5 years of screening, excluding basal cell or squamous cell skin cancer, cervical cancer in situ, or prostate cancer that does not currently or is not expected to require radiotherapy, chemotherapy, and / or surgical intervention or start hormone therapy. 24. History of organ transplantation. 25. Receipt of COVID-19 vaccine less than 1 week prior to dosing (Visit 2 / Day 1) and / or plans to receive COVID-19 vaccine during the study period. 26. History of severe drug abuse within one year prior to screening, or frequent use of soft drugs (such as marijuana) within 3 months prior to the screening visit, or frequent use of hard drugs (such as cocaine, phencyclidine [PCP], opioid derivatives including heroin, and amphetamine derivatives) within one year prior to screening. 27. History of alcoholism in the past 2 years or current evidence of excessive drinking as assessed by screening evaluation using the Alcohol Use Disorders Identification Test (AUDIT, Thompson 2018), and a history of usual drinking exceeding approximately 14 drinking units / week (males) and 7 drinking units / week (females) [1 drinking unit = 4 ounces (120 mL) of wine or 12 ounces (360 mL) of beer or 1 ounce (30 mL) of spirits] within 6 months of screening, as determined by the investigator. 28. Positive urine drug screen for drugs of abuse at screening, or positive phosphatidylethanol (PEth) blood test result >100 ng / mL. In the case of an exclusionary PEth value, the subject may be considered for inclusion if the principal investigator and medical monitor agree that the subject's medical history is inconsistent with alcohol abuse. 29. Current regular use of e-cigarettes or more than 5 cigarettes or equivalent per week. Use of nicotine patches to quit smoking is permitted. 30. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV1 / 2) antibody. 31. Neutropenia, defined as an absolute neutrophil count ≤1000 / μL. 32. Serum AST or ALT>5x upper limit of normal (ULN) at screening. (One repeat test within 7 days may be allowed at the discretion of the investigator). 33. Total bilirubin >ULN unless due to Gilbert's syndrome or approved by the Medical Monitor and considered normal variability in the absence of other clinically relevant liver impairment. 34. If there is other evidence of potential severe liver injury, the international normalized ratio (INR) should be ≥1.3 at screening. 35. Participation in another clinical trial at the time of screening, or exposure to any investigational drug (including topical investigational drugs) within 30 days or 5 half-lives (if half-life is known) of screening. 36. No tattoos or body piercings during the study. Any underlying physical or mental medical condition that, in the opinion of the Investigator or Sponsor, would make the subject less likely to be able to comply with the study requirements or to complete the study. 37. Any circumstances that the investigator believes will interfere with the subject's ability to provide written informed consent, comply with study instructions, or may confound the interpretation of study results or place the subject at unnecessary risk. 38. Known or potential hypersensitivity to Compound 1 or its excipients. Prohibited drugs (current use): 39. Any herbal supplement, over-the-counter, mail-order, or prescription drug used for weight loss. 40. Prescription or over-the-counter stimulants, including: dextroamphetamine / Dexedrine, dextroamphetamine / amphetamine combination products / Adderall, or methylphenidate 41. Thiazolidinediones (TZDs): pioglitazone / Actos, rosiglitazone / Avandia. 42. Glucagon-like peptide 1 (GLP1) agonists: Exenatide / Byetta / Bydureon, Lixisenatide / Adlyxin, Liraglutide / Victoza, Dulaglutide / Trulicity, Semaglutide / Ozempic. 43. Sodium-glucose co-transporter-2 (SGLT2) inhibitors: canagliflozin / Invokana, dapagliflozin / Farxiga, empagliflozin / Jardiance, erigoflozin / Steglatro. 44. Vitamin E: Use of ursodiol or high-dose vitamin E > 400 IU / day for at least one month in the past 6 months, or initiation of high-dose vitamin E within the last 3 months of screening. 45. Recent (within 3 months of screening) or current use of obeticholic acid / Ocaliva, systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or chronic use of tetracycline. 46. ​​Warfarin, heparin, factor Xa inhibitors (dabigatran, betrixaban, edoxaban, apixaban, and rivaroxaban). 47. Concomitant medications that prolong the QT / QTc interval and are known to be associated with an increased risk of Torsades de Pointes, as identified in the “Known Risks” category of the https: / / crediblemeds.org / website listing. 48. Products containing cannabidiol (CBD).

[0111] Phase 2a trial results The Phase 2a metabolic trial of Compound 1 was a 61-day randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy of three dose levels of Compound 1 (150 mg, 300 mg, and 450 mg) in obese participants (BMI 28 to 45 kg / m2) with elevated liver fat (greater than 8%). 2) in the Phase 2a trial. Eighty (80) participants, ranging in age from 28 to 65 years, were randomized to one of three Compound 1 treatment groups or a matching placebo group, stratified and blocked for HbA1c levels of 5.7% or higher, and dosed once daily (fasting). Participants were instructed not to change their behavior in terms of diet or exercise. The Phase 2a trial met the primary endpoint (reduction in liver fat measured by MRI-PDFF) and secondary endpoints (reduction in weight and fat measured by abdominal MRI). Key results and observations include: ●Without changes in eating or exercise behavior, weight loss at eight weeks at all dosing levels was almost exclusively from loss of fat, with preservation of lean body mass. o Weight and fat loss was greatest at the highest dosing level, with participants losing an average of 6 pounds (high dose vs. placebo, p<0.001). o Participants with elevated HbA1c levels experienced greater weight and fat loss, with an average loss of 10 pounds (high dose vs. placebo, p<0.0001). o Fat reduction was observed in the liver, visceral, and subcutaneous compartments by MRI. ○ Absolute reductions in liver fat >30% were observed by MRI-PDFF: 40%, 71%, and 72% for Compound 1 at the 150 mg, 300 mg, and 450 mg dose levels, respectively, and in the HbA1c subset were 43%, 75%, and 86% for Compound 1 doses, respectively, compared to 0-5% for placebo (P<0.05 for all). ○ Relative reductions in liver fat were 33%, 43%, and 40% at the low, mid, and high doses, respectively, compared to a 2% relative reduction in liver fat and a 5% responder rate with placebo, corresponding to responder rates (>30% relative reduction) of 40%, 71%, and 72%. Compound 1 was well tolerated at all dose levels with excellent compliance. No serious adverse events or deaths were reported. Diarrhea and transient flushing associated with alcohol ingestion, which occurred in 25% and 31.6% of Compound 1 subjects, respectively, were the most frequently reported treatment-emergent adverse events. These events were mostly mild; in the low-dose group, one participant discontinued Compound 1 due to diarrhea, whereas at the high dose, no participants discontinued for any reason. Short-term treatment with Compound 1 was associated with significant improvements in primary and secondary endpoints for NAFLD and obesity. The safety and tolerability of Compound 1, combined with its ability to reduce liver and systemic fat gain in subjects regardless of HbA1c status, suggests that long-term treatment with Compound 1 has the potential to be an effective treatment for NAFLD and other obesity-related metabolic diseases. ●150mg, 300mg and 450mg of compound 1 showed significant dose-related positive effects on the primary efficacy endpoint of changes in liver fat content measured by MRI-PDFF in the overall population and those with elevated HbA1c, and these changes occurred within 61 days of treatment. The placebo-corrected changes relative to baseline using compound 1 ranged from 0.6& to -7%, which is favorable compared to other short-term Phase 2 studies of drugs for NAFLD (Harrison et al., 2021; Loomba et al., 2020). Based on MRI-PDFF, approximately 60% of the overall subjects and approximately 68% of the subjects in the subgroup experienced at least 30% reduction in liver fat, and the placebo-corrected mean percentage change relative to baseline for the overall subjects ranged from -33% to 43% and the subjects in the subgroup were -42% to -50%. The reduction in liver fat content was accompanied by a reduction in weight, which was explained by body fat, and there was no reduction in lean body mass. Improvements in liver volume, SAT, and CAP scores occurred with Compound 1 in the overall group and in the subgroup with elevated HbA1c. At doses of 300 mg and 450 mg, Compound 1 exhibited significant positive effects on several endpoints (including InBody scale measurements of body weight, body fat mass, and body fat percentage), without significant effects on skeletal muscle mass, lean body mass, or dry lean body mass. Compared with placebo, the 450 mg group had an average weight reduction of 6 pounds on day 61, and the subgroup of subjects with elevated HbA1c reduced by 10 pounds, while skeletal muscle mass (and lean body mass and dry lean body mass) remained unchanged. Significant reductions in inflammatory and metabolic markers were observed with Compound 1. Glycated albumin was used in this study instead of HbA1c to assess metabolic control because changes in glycated albumin occurred earlier than HbA1c (120 days) and were a better marker of glycemic control in this 61-day study. A 0.5% reduction in HbA1c was observed, which occurred simultaneously with a statistically significant greater reduction in glycated albumin. Prioritizing fat reduction and improving glycemic control in subjects with elevated HbA1c is of interest and because long-term therapy has the potential to improve metabolic and inflammatory health in patients with type 2 diabetes and obesity. ●The results showed that treatment with compound 1 improved the FAST score, and this improvement had a clinically relevant magnitude and was evident at the lowest dose used (150 mg). The FAST score is a non-invasive test for identifying patients with progressive liver fibrosis. Non-alcoholic fatty liver disease has a high prevalence, especially in obese and type 2 diabetic patient populations. Some patients can tolerate elevated liver fat levels without disease progression, while other patients progress to NASH. Currently, a definitive diagnosis of NASH requires a liver biopsy and histological scoring, an invasive and time-consuming diagnostic procedure associated with certain risks. The challenge of identifying patients with progressive disease puts patients at risk of progressing to the later stages of NASH without intervention. Fibroscan is a non-invasive ultrasound-based measurement of liver elasticity and hardness that provides a measure of fibrosis. Aspartate aminotransferase (AST) is a liver enzyme that can be measured in a blood sample, and elevated levels indicate liver damage. Combined Fibroscan and AST levels (FAST score) have been shown to provide valuable indicators for patients with progressive fibrosis (Woreta et al. PLoS One 2022 Apr 15; 17(4): e0266859, https: / / doi.org / 10.1371 / journal.pone.0266859). A relatively small decrease of 0.2 points in the FAST score has been shown to provide improvements in several clinical measures in patients diagnosed with NASH (Wong et al., J. of Hepatology Vol. 75, pp. S257-S258 2021; Newsome et al., The N England J of Medicine 2021; 384: 1113-24). Therefore, the present disclosure provides a method for treating a subject with an elevated FAST score, wherein the subject is experiencing disease progression. In some embodiments, the method reduces the patient's FAST score to reduce the risk of disease progression. In some embodiments, disease progression includes progressive fibrosis, progressive NASH and / or progressive fibrotic liver disease NASH. NASH is a form of NAFLD that features liver inflammation and liver damage in addition to fat in the liver. The inflammation and liver damage of NASH can cause fibrosis, or scarring, of the liver. NASH can lead to cirrhosis, in which the liver becomes scarred and permanently damaged. Our data further suggest that compound 1 is effective at lower dose levels for treating patients with HbA1c levels between 5.7%-9.0% in NASH, a progressive fibrotic liver disease. Detailed efficacy and safety results for Phase 2a are shown in the figures and tables below:

[0112] (1) Figure 2 As shown in Table 1 below, in subjects with elevated HbA1c, treatment effects were demonstrated at all doses in terms of relative liver fat changes, as placebo-corrected percent change in MRI proton density fat fraction (PDFF) from baseline values ​​in subjects with HbA1c 5.7%-9.0% (mean ± SEM). Table 1 Baseline is the last nonmissing value before the first dose of study drug; SD stands for standard deviation.

[0113] (2) MRI-Analysis of covariance for proton density fat fraction (PDFF) is shown in Table 2. Mean change from baseline on Day 61 for subjects with HbA1c 5.7%-9.0%. Subgroup only (LS mean ± 95% CI). Table 2 Note: This analysis was performed using a model that included treatment as a fixed effect and baseline HbA1c stratification as a factor, and baseline value of the response variable as a covariate Note: LS = least squares method, CI = confidence interval

[0114] (3) Treatment resulted in responses in all dose groups (>30% reduction in liver fat as measured by MRI-PDFF), as shown in Table 3 below: Table 3

[0115] (4) Figure 3 and Table 4a below, significant weight loss (lbs) in subjects with elevated HbA1c, repeated measures analysis of InBody Weight. Mean Change from Baseline FAS Population (LS Mean ± 95% CI). Data for the total patient population are in Table 4b. Table 4a Table 4b LS = least squares, SEM = standard error of the mean, CI = confidence interval. The MMRM analysis was performed with a model that included the effects of treatment, visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c stratification as a factor and the baseline value of the response variable as a covariate.

[0116] (5) Fat loss (mean ± SEM) in the group of subjects with elevated HbA1c is shown in Figure 4 middle.

[0117] (6) Weight loss in the overall population and in the elevated HbA1c group is shown in Figure 5 The percent body weight change at Day 61 (using 450 mg Compound 1) was -2.55% in the overall population (FAS) subjects and -4% in subjects with high HbA1c.

[0118] (7) Body fat mass decreased in the elevated HbA1c group as shown in Table 5 and in the overall group as shown in Table 6. In the patient group with elevated HbA1c, the decrease in body fat mass was greater. Table 5 Repeated measures analysis of mean change from baseline in selected secondary InBody parameters in subjects in the HbA1c 5.7%-9.0% subgroup only FAS Group Table 6 Repeated Measures Analysis of Mean Change from Baseline in Selected Secondary InBody Parameters FAS Group In Tables 5 and 6: LS = least squares, SEM = standard error of the mean, CI = confidence interval

[0119] (8) The response rate of liver fat reduction from baseline to day 61 (i.e., ≥30%) is shown in Figure 6 middle.

[0120] (9) The absolute and relative percentage changes (%) in liver fat at 150 mg, 300 mg and 450 mg of Compound 1 (from baseline to day 61) are shown in Figure 7 middle.

[0121] (10) The percentage changes (%) of liver stiffness parameters relative to baseline at 150 mg, 300 mg and 450 mg of Compound 1 are shown in Figure 8 middle.

[0122] (11) The reduction in glycated albumin from baseline to day 61 (percent change (%)) is shown in Tables 7 and Fig. 9 middle. Table 7 Summary statistics of observed values ​​and changes from baseline in percentage (%) of glycated albumin by treatment group FAS Group

[0123] (12) The LS mean changes in liver parameters on day 61 are shown in Table 8 below: Table 8 The analysis was performed using a model including treatment as a fixed effect and baseline HbA1c stratification as a factor, and the baseline value of the response variable as a covariate. ap<0.05; bp<0.01; cp<0.001.

[0124] (13) The change (%) in MRI-proton density fat fraction from baseline to Day 61 in all subjects and in the subgroup of subjects with elevated HbA1c is shown in Table 9. Table 9

[0125] (14) The changes in liver volume and total body fat gain from baseline to Day 61 in all subjects and in the subgroup of subjects with elevated HbA1c are shown in Table 10. Table 10 Abbreviations: ANCOVA = analysis of covariance; FAS = full analysis set; HbA1c = hemoglobin A1c; LS = least squares. a Negative values ​​indicate a decrease in the parameter value. b LS means and associated 95% CIs for changes from baseline, differences in LS means and associated 95% CIs, and two-sided p-values ​​were derived from ANCOVA models with treatment as fixed effect, baseline HbA1c strata as factors, and baseline parameter values ​​as covariates.

[0126] In summary, 150mg, 300mg and 450mg of compound 1 showed significant dose-related positive effects on the primary efficacy endpoint of changes in liver fat content measured by MRI-PDFF relative to baseline in the overall population and those with elevated HbA1c, and these changes occurred within 61 days of treatment. Based on MRI-PDFF, approximately 60% of the overall subjects and approximately 68% of the subjects in the subgroup experienced at least 30% liver fat reduction, and the placebo-corrected mean percentage change relative to baseline for the overall subjects ranged from -33% to -43% and -42% to -50% for the subjects in the subgroup. The reduction in liver fat content was accompanied by a reduction in body weight, which was explained by body fat, and there was no reduction in lean body mass. In the overall group and the subgroup with elevated HbA1c, improvements in liver volume, SAT and CAP scores occurred with compound 1.

[0127] In addition, the 300 mg and 450 mg doses of Compound 1 demonstrated significant positive effects on several secondary endpoints, including In Body scale measurements of body weight, body fat mass, and body fat percentage, while having no effect on skeletal muscle mass, lean body mass, or dry lean body mass. Compared with placebo, the 450 mg group had a mean body weight reduction of 6 pounds on day 61, and a subgroup of subjects with elevated HbA1c reduced 10 pounds, while skeletal muscle mass (as well as lean body mass and dry lean body mass) remained unchanged. Significant reductions in inflammatory and metabolic markers were observed with Compound 1. Glycated albumin was used in this study rather than HbA1c to assess metabolic control because changes in glycated albumin occurred earlier than HbA1c (120 days) and were a better marker of glycemic control in this 61-day study. A 0.5% reduction in HbA1c was observed, concurrent with a statistically significant greater reduction in glycated albumin. Prioritizing fat reduction and improving glycemic control in subjects with elevated HbA1c is of interest and because long-term therapy has the potential to improve metabolic and inflammatory health in patients with type 2 diabetes and obesity.

Claims

1. A method for weight loss in a subject having abnormal HbA1c levels, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

2. A method for reducing body fat mass in a subject with abnormal HbA1c levels, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 or 2, wherein the abnormal HbA1c level is elevated HbA1c.

4. The method of claim 3, wherein the subject has an elevated HbA1c level greater than 5.

7.

5. A method for treating non-alcoholic fatty liver disease (NAFLD) in a subject with elevated liver fat, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

6. A method for reducing liver fat in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

7. The method of any one of claims 1-6, wherein the subject has a high body mass index.

8. The method of claim 7, wherein the subject has a blood pressure greater than 28.0 kg / m 2 body mass index.

9. The method of claim 6, wherein the subject has a body weight between 28.0-45.0 kg / m 2 between body mass index.

10. The method according to any one of claims 5-9, wherein the subject has elevated HbA1c levels.

11. The method of claim 10, wherein the subject has an elevated HbA1c level greater than 5.

7.

12. The method of any one of claims 6-11, wherein the reduction in liver fat in the subject is at least 30%.

13. The method according to any one of claims 6-12, wherein the therapeutically effective amount is 150 mg.

14. The method of claim 13, wherein the method results in a reduction of about 40% in liver fat in the subject.

15. The method of claim 13, wherein the method results in a reduction in liver fat of about 43% in the subject having elevated HbA1c levels.

16. The method of any one of claims 6-12, wherein the therapeutically effective amount is 300 mg.

17. The method of claim 15, wherein the method results in a reduction in liver fat of about 70% in the subject.

18. The method of claim 15, wherein the method results in a reduction in liver fat of about 75% in the subject having elevated HbA1c levels.

19. The method of any one of claims 6-12, wherein the therapeutically effective amount is 450 mg.

20. The method of claim 19, wherein the method results in the subject having a liver fat of about 72%.

21. The method of claim 19, wherein the method results in a liver fat of about 86% in the subject having elevated HbA1c levels.

22. The method of any one of the preceding claims, wherein the method slows the progression of non-alcoholic fatty liver disease.

23. The method of any of the preceding claims, wherein the subject suffers from obesity, excess body fat, diabetes, high blood pressure / hypertension, dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.

24. The method of any one of the preceding claims, wherein the subject suffers from obesity or excess body fat.

25. The method of any one of the preceding claims, wherein the subject suffers from diabetes.

26. The method of claim 24, wherein the diabetes is type 2 diabetes mellitus (T2DM).

27. The method according to any one of the preceding claims, wherein the subject suffers from a disorder selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

28. The method of any one of the preceding claims, wherein the subject suffers from at least one symptom selected from decreased exercise tolerance, fatigue, tiredness, increased recovery time after exercise, and ankle swelling.

29. A method for reducing the FAST score of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

30. The method of claim 29, wherein the method reduces the risk of disease progression in the subject.

31. The method of claim 30, wherein the disease progression is progressive fibrosis or progressive fibrosing liver disease NASH.

32. A method for treating fibrosis, progressive fibrosis or progressive fibrosing liver disease (NASH) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.

33. The method of any one of claims 29-32, wherein the subject has a high body mass index.

34. The method of claim 33, wherein the subject has a blood pressure greater than 28.0 kg / m 2 body mass index.

35. The method of claim 33, wherein the subject has a body weight between 28.0-45.0 kg / m 2 between body mass index.

36. The method of any one of claims 29-35, wherein the subject has elevated HbA1c levels.

37. The method of claim 36, wherein the subject has an elevated HbA1c level greater than 5.

7.

38. The method of any one of claims 1-12 or 29-37, wherein the therapeutically effective amount is from about 30 mg to about 1400 mg per day, from about 50 mg to about 100 mg per day, from about 150 mg to about 600 mg per day, or from 200 mg to 550 mg per day.

39. The method of any one of claims 1-12 or 29-37, wherein the therapeutically effective amount is about 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg or 600 mg per day.

40. The method of any one of claims 1-12 or 29-37, wherein the therapeutically effective amount is about 150 mg, 300 mg, or 450 mg per day.

41. The method of any one of claims 1-12 or 29-37, wherein the therapeutically effective amount is about 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg or 95 mg per day.

42. The method of any one of claims 1-12 or 29-37, wherein 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is administered orally once daily.

43. The method of any of the preceding claims, wherein the subject experiences greater than 5%, 10%, 20%, 30% or 40% weight loss.

44. The method of any of the preceding claims, wherein the subject experiences approximately 40% weight loss.

45. The method of claim 34, wherein the therapeutically effective amount is about 150 mg and the weight loss is greater than 10%.

46. ​​The method of claim 34, wherein the therapeutically effective amount is about 300 mg and the weight loss is greater than 20%.

47. The method of claim 34, wherein the therapeutically effective amount is about 450 mg and the weight loss is greater than 30%.

48. The method of any one of claims 1-11, wherein the subject experiences at least one of: i) weight loss of at least 5% or at least 30%; ii) blood pressure decreased by at least 5 mmHg; iii) HbA1c reduction of at least 0.5%; iv) a reduction in lipids by at least 10%; and / or v) Liver fat reduction of at least 30%.

49. The method of any one of the preceding claims 1-11, wherein the subject experiences at least one of: i) weight loss of at least 5% or at least 30%; ii) blood pressure decreased by at least 5 mmHg; iii) HbA1c reduction of at least 0.5%; iv) a reduction in lipids by at least 10%; and / or v) Reduction of liver fat by at least 50%.

50. The method of claim 48 or 49, wherein the subject experiences a reduction in HbA1c of greater than 1.5%.

51. The method of any one of the preceding claims, wherein the method slows the progression of obesity, hypertension or diabetes.